Intratumour heterogeneity, from hypothesis to the clinic

SUMMARY Recent technological advances uncovered intricate biological processes underlying intratumor heterogeneity with clinical implications. These insights led to novel biomarkers for

immunotherapies, justified serial tumour biopsies for therapeutic target profiling, inspired new treatment strategies, and ultimately might yield novel therapeutics that target clonal

interdependence. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution

Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full

article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *

Contact customer support DATA AVAILABILITY Not applicable. REFERENCES * Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer.

2013;108:479–85. Article  CAS  PubMed  PubMed Central  Google Scholar  * Jiang T, Shi W, Natowicz R, Ononye SN, Wali VB, Kluger Y, et al. Statistical measures of transcriptional diversity

capture genomic heterogeneity of cancer. BMC Genomics. 2014;15:876. Article  PubMed  PubMed Central  Google Scholar  * McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution:

past, present, and the future. Cell. 2017;168:613–28. Article  CAS  PubMed  Google Scholar  * Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, et al. Immune gene expression is

associated with genomic aberrations in breast cancer. Cancer Res. 2017;77:3317–24. Article  CAS  PubMed  Google Scholar  * Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the

rosetta stone of therapy resistance. Cancer Cell. 2020;37:471–84. Article  CAS  PubMed  PubMed Central  Google Scholar  * Vitale I, Shema E, Loi S, Galluzzi L. Intratumoral heterogeneity in

cancer progression and response to immunotherapy. Nat Med. 2021;27:212–24. Article  CAS  PubMed  Google Scholar  * Beerenwinkel N, Schwarz RF, Gerstung M, Markowetz F. Cancer evolution:

mathematical models and computational inference. Syst Biol. 2015;64:e1–e25. Article  CAS  PubMed  Google Scholar  * Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in

metastasis. Cancer Cell. 2020;37:8–19. Article  CAS  PubMed  Google Scholar  * Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma

during BRAF inhibitor therapy. Cancer Discov. 2014;4:80–93. Article  CAS  PubMed  Google Scholar  * Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, et al. Evolution and

clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49:1693–704. Article  CAS  PubMed  PubMed Central  Google Scholar  * Juric D,

Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature. 2015;518:240–4. Article  CAS  PubMed  Google

Scholar  * Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number

aberrations. Nat Commun. 2017;8:14944. Article  PubMed  PubMed Central  Google Scholar  * Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, et al. Transient commensal

clonal interactions can drive tumor metastasis. Nat Commun. 2020;11:5799. Article  CAS  PubMed  PubMed Central  Google Scholar  * Patwardhan GA, Marczyk M, Wali VB, Stern DF, Pusztai L,

Hatzis C. Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations. NPJ Breast Cancer. 2021;7:60. Article  CAS  PubMed  PubMed Central 

Google Scholar  * Reeves MQ, Kandyba E, Harris S, Del Rosario R, Balmain A. Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma evolution from initiation to metastasis.

Nat Cell Biol. 2018;20:699–709. Article  CAS  PubMed  PubMed Central  Google Scholar  * Maddipati R, Stanger BZ. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer

Discov. 2015;5:1086–97. Article  CAS  PubMed  PubMed Central  Google Scholar  * Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour

growth supports sub-clonal heterogeneity. Nature. 2014;514:54–8. Article  CAS  PubMed  PubMed Central  Google Scholar  Download references FUNDING None. AUTHOR INFORMATION AUTHORS AND

AFFILIATIONS * Yale Cancer Center, Yale School of Medicine, 333 Cedar St., PO Box 208032, New Haven, CT, 05620, USA Naing Lin Shan, Adriana Kahn & Lajos Pusztai Authors * Naing Lin Shan

View author publications You can also search for this author inPubMed Google Scholar * Adriana Kahn View author publications You can also search for this author inPubMed Google Scholar *

Lajos Pusztai View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Contributing authors for manuscript preparation: NLS, AK and LP. All authors

reviewed the manuscript and approved the final version of the manuscript. CORRESPONDING AUTHOR Correspondence to Lajos Pusztai. ETHICS DECLARATIONS COMPETING INTERESTS LP has received

consulting fees and honoraria from Pfizer, AstraZeneca, Merck, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Personalis, Daiichi, Natera, Exact Sciences and institutional

research funding from Seagen, GlaxoSmithKline, AstraZeneca, Merck, Pfizer and Bristol-Myers Squibb. ETHICS APPROVAL AND CONSENT TO PARTICIPATE Not applicable. CONSENT TO PUBLISH Not

applicable. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Shan, N.L., Kahn, A. & Pusztai, L. Intratumour heterogeneity, from hypothesis to the clinic. _Br J Cancer_ 128,

459–460 (2023). https://doi.org/10.1038/s41416-022-02008-w Download citation * Received: 08 September 2022 * Revised: 27 September 2022 * Accepted: 29 September 2022 * Published: 10 October

2022 * Issue Date: 02 February 2023 * DOI: https://doi.org/10.1038/s41416-022-02008-w SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative